Table 3 The treatment regimens and prognosis for all the patients and the subgroup divided by family cluster.
Treatment and outcomes | All patients (N = 37) | Familial cluster | ||
|---|---|---|---|---|
Yes (N = 21) | No (N = 16) | P value | ||
Antiviral treatment | 0.763 | |||
Lipinavir/ritonavir + interferon alpha inhalation | 14 (38.9%) | 7 (35.0%) | 7 (43.8%) | |
Lipinavir/ritonavir + interferon alpha inhalation + peginterferon | 6 (16.7%) | 3 (15.0%) | 3 (18.8%) | |
lipinavir/ritonavir + interferon alpha inhalation + arbidol | 1 (2.8%) | 1 (5.0%) | 0 (0.0%) | |
Arbidol + interferon alpha inhalation + ribavirin | 1 (2.8%) | 1 (5.0%) | 0 (0.0%) | |
Interferon alpha inhalation | 3 (8.3%) | 1 (5.0%) | 2 (12.5%) | |
Lipinavir/ritonavir + interferon alpha inhalation + antibolics | 6 (16.7%) | 3 (15.0%) | 3 (18.8%) | |
Interferon alpha inhalation + antibolics | 2 (5.6%) | 1 (5.0%) | 1 (6.2%) | |
Interferon alpha inhalation + ribavirin | 2 (5.6%) | 2 (10.0%) | 0 (0.0%) | |
Interferon alpha inhalation + arbidol | 1 (2.8%) | 1 (5.0%) | 0 (0.0%) | |
Prognosis | 0.333 | |||
Admission days | 27.0 (24.0–34.0) | 27.0 (23.8–33.2) | 29.0 (25.0–39.5) | |
